TECH - Bio-Techne Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
207.87
-0.89 (-0.43%)
As of 3:25PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close208.76
Open209.45
Bid207.58 x 900
Ask207.79 x 800
Day's Range206.14 - 209.45
52 Week Range132.75 - 217.16
Volume156,297
Avg. Volume142,682
Market Cap7.872B
Beta (3Y Monthly)1.35
PE Ratio (TTM)66.33
EPS (TTM)3.13
Earnings DateAug 6, 2019
Forward Dividend & Yield1.28 (0.61%)
Ex-Dividend Date2019-05-09
1y Target Est220.83
Trade prices are not sourced from all markets
  • PR Newswire6 hours ago

    Uman Diagnostics And Bio-Techne Announce License And Supply Agreement For Neurofilament Light Assay

    MINNEAPOLIS, July 23, 2019 /PRNewswire/ -- Uman Diagnostics, now part of Quanterix, and Bio-Techne announced today a strategic License and Supply Agreement for the antibodies used in the quantification of neurofilament light (Nf-L) on the ProteinSimple™-branded Ella™ immunoassay platform. Under the terms of the agreement, Uman Diagnostics will supply Nf-L antibodies to Bio-Techne for use in its proprietary Simple Plex™ immunoassays on Ella.

  • CBM or TECH: Which Is the Better Value Stock Right Now?
    Zacksyesterday

    CBM or TECH: Which Is the Better Value Stock Right Now?

    CBM vs. TECH: Which Stock Is the Better Value Option?

  • PR Newswire5 days ago

    Bio-Techne To Host Conference Call On August 6, 2019, To Announce Fourth Quarter 2019 Financial Results

    MINNEAPOLIS , July 18, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, August 6, 2019 , at 8:00 a.m. CDT to review fourth ...

  • PR Newswire6 days ago

    Bio-Techne Releases 32x8 Cartridge For The Ella Platform

    MINNEAPOLIS , July 17, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of a new 8-Plex cartridge format for the ProteinSimple™-branded Ella™ automated immunoassay ...

  • PR Newswire12 days ago

    Bio-Techne Announces Commercial Release Of RNAscope® HiPlex Assay: A Multiplex In Situ Hybridization Assay For Tissues

    Expanding research tools for Spatial Genomics by combining molecular information with spatial context in one simple assay. MINNEAPOLIS , July 11, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) ...

  • Why the Earnings Surprise Streak Could Continue for Techne (TECH)
    Zacks14 days ago

    Why the Earnings Surprise Streak Could Continue for Techne (TECH)

    Techne (TECH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Bio-Techne CEO Chuck Kummeth Wins Entrepreneur Of The Year® 2019 Award In The Heartland
    PR Newswire14 days ago

    Bio-Techne CEO Chuck Kummeth Wins Entrepreneur Of The Year® 2019 Award In The Heartland

    MINNEAPOLIS, July 9, 2019 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced that its President and CEO, Chuck Kummeth, was recently honored with the EY Entrepreneur Of The Year® 2019 Award in the Heartland. The EY awards program recognizes entrepreneurs and leaders of high-growth companies who are excelling in areas such as innovation, financial performance, and personal commitment to their businesses and communities, while also transforming the world. Mr. Kummeth was chosen by an independent panel of judges as one of a select few that are not only driving their companies' success, but are also transforming their industries by creating new solutions, innovations, and possibilities.

  • GuruFocus.com21 days ago

    Baron Capital Commentary: Early Detection for the Win

    Three stock picks using new technology that could revolutionize the fight against cancer

  • At US$209, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
    Simply Wall St.21 days ago

    At US$209, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

    Bio-Techne Corporation (NASDAQ:TECH), which is in the life sciences business, and is based in United States, saw a...

  • Bio-Techne China Recognized With "Decade of Contribution Award"
    PR Newswire27 days ago

    Bio-Techne China Recognized With "Decade of Contribution Award"

    MINNEAPOLIS , June 26, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) was recently honored with the "Decade of Contribution Award" at the 2019 (10th) International Conference on Cell ...

  • PR Newswire28 days ago

    Bio-Techne Appoints Rupert Vessey to Board of Directors

    MINNEAPOLIS , June 25, 2019 /PRNewswire/ -- Bio-Techne Corporation today announced the appointment of Dr. Rupert Vessey to the company's Board of Directors as an independent director.  Dr. Vessey's appointment ...

  • Here’s What Hedge Funds Think About Bio-Techne Corporation (TECH)
    Insider Monkeylast month

    Here’s What Hedge Funds Think About Bio-Techne Corporation (TECH)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 8 months is one of those periods, as the Russell 2000 […]

  • GuruFocus.comlast month

    Royce Funds Commentary: Lauren Romeo on 4 Quality Cyclicals

    By Portfolio Manager and Principal Lauren Romeo, CFA

  • PR Newswirelast month

    FDA Grants Breakthrough Device Designation To Bio-Techne's ExoDx™ Prostate IntelliScore™ (EPI) Test

    MINNEAPOLIS , June 17, 2019 /PRNewswire/ -- Bio-Techne today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its ExoDx Prostate IntelliScore (EPI) ...

  • PR Newswirelast month

    Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State

    MINNEAPOLIS, June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York, providing a valuable tool to help Urologists rule out unnecessary prostate biopsies. The EPI test was launched in the U.S. in 2017. With this approval, the EPI test is now available to Urologists in New York State.

  • Markitlast month

    See what the IHS Markit Score report has to say about Bio-Techne Corp.

    Bio-Techne Corp NASDAQ/NGS:TECHView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for TECH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TECH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $894 million over the last one-month into ETFs that hold TECH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • If You Like EPS Growth Then Check Out Bio-Techne (NASDAQ:TECH) Before It's Too Late
    Simply Wall St.2 months ago

    If You Like EPS Growth Then Check Out Bio-Techne (NASDAQ:TECH) Before It's Too Late

    It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

  • The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

  • Myriad Genetics Announces Study Results Of myRisk Cancer Test
    Zacks2 months ago

    Myriad Genetics Announces Study Results Of myRisk Cancer Test

    The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

  • PR Newswire2 months ago

    Bio-Techne To Acquire B-MoGen Biotechnologies Inc.

    MINNEAPOLIS, June 4, 2019 /PRNewswire/ -- Bio-Techne Corporation (TECH) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc. The transaction has been completed and is being financed through available cash on hand. "We are very pleased to include the B-MoGen technology in Bio-Techne's expanding portfolio of products that serve the rapidly growing cell and gene therapy markets," commented Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne.  "B-MoGen's technologies solve the most complex gene editing problems with proprietary, cutting edge gene editing and delivery tools, enabling and accelerating growth in immunotherapy treatments.

  • 5 Biotech Stocks to Buy Right Now
    Zacks2 months ago

    5 Biotech Stocks to Buy Right Now

    here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.

  • Bio-Techne To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
    PR Newswire2 months ago

    Bio-Techne To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

    MINNEAPOLIS , June 3, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Goldman Sachs 40 th Annual ...